Sign in
Join
Discovery/Preclinical
In vitro
In vivo
Newer Targets
Clinical
Approval
FDA/EMA/Drug Designation
IND
Launch
NDA
Phase I
Phase II
Phase III
Recall
Commercial
Acquisitions
Conference/Award
Deals
Financial
Lawsuits/Bankruptcy
Lay off/Spin-off/Appointments
Merger
Patent
Pricing
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Sign up
Welcome!
Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
Search
Sign in / Join
Contact
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Discovery/Preclinical
All
In vitro
In vivo
Newer Targets
In vivo
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38?…
Newer Targets
Targeting a key protein may keep ovarian cancer cells from spreading
Newer Targets
Marathon-running molecule could speed up the race for new neurological treatments
Newer Targets
Targeting a key protein may keep ovarian cancer cells from spreading
Clinical
All
Approval
FDA/EMA/Drug Designation
IND
Launch
NDA
Phase I
Phase II
Phase III
Recall
Phase II
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for…
Approval
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application…
Phase I
Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial…
Phase II
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for…
Commercial
All
Acquisitions
Conference/Award
Deals
Financial
Lawsuits/Bankruptcy
Lay off/Spin-off/Appointments
Merger
Patent
Pricing
Deals
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi…
Deals
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part…
Commercial
Novartis Close to Settling Kickback Lawsuit
Deals
Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data…
Home
Commercial
Acquisitions
Acquisitions
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Acquisitions
PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
Biospace News
-
July 17, 2019
Acquisitions
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
Acquisitions
Roche’s $4.8 Billion Acquisition of Spark Pushed Back to April 2020
Acquisitions
SIFI announces expansion on the French market with the acquisition of DACUDOSES and NOVOPTINE
Acquisitions
Evotec completes acquisition of Just Biotherapeutics
Acquisitions
Acura Pharmaceuticals Licenses LIMITx LTX-03
Firstwordpharma News
-
July 2, 2019
0
Acquisitions
Novartis successfully completes acquisition of Xiidra, bolstering ophthalmic portfolio
Firstwordpharma News
-
July 1, 2019
0
Acquisitions
AbbVie’s Latest Acquisition Offers Solution for ‘Life After Humira’
Biospace News
-
June 26, 2019
0
Acquisitions
AbbVie Makes ‘Transformational’ Move with $63 Billion Acquisition of Allergan
Biospace News
-
June 25, 2019
0
Acquisitions
Bristol-Myers Squibb Plans to Sell Celgene’s Otezla in Attempt to Expedite...
Biospace News
-
June 24, 2019
0
1
2
3
...
15
Page 1 of 15
- Advertisement -
MOST POPULAR
Ford government to fund Spinraza, world’s most expensive drug – with...
June 12, 2019
BMS Releases Details of Failed CheckMate 451 Trial at European Lung...
April 12, 2019
Release of Federal Database Reveals 76 Billion Opioid Pills Were Sold...
July 17, 2019
Scottish Medicines Consortium dasatinib (Sprycel)
May 13, 2019
Load more
HOT NEWS
Commercial
Free report: TOP 25 Pharma Groups analyzed for sales, R&D costs,...
Commercial
Pink Slips Continue to Hit California Life Science Companies
Commercial
Karuna Completes $80 Million Series B Financing
Others
Scottish Medicines Consortium Positive Recommendation for Darzalex Offers Alternative Second-line Treatment...
